To take part in this event, you must register in advance. REGISTER NOW Access the live stream from 17:30 CEST on Tuesday 1 October, 2024 WATCH LIVE 1 October, 2024 | Online17:30-18:30 CEST Overview Taking place on 1 October, this ERS Vision Live panel discussion is entitled 'Bronchiectasis Update'.   The expert panellists will discuss key areas, including:   Tackling inflammation in bronchiectasis - Michal ShteinbergComorbidities of bronchiectasis - Letizia TraversiDiagnosing rare conditions causing bronchiectasis like primary ciliary dyskinesia or cystic fibrosis - Felix Ringshausen This event is free to access but registration is required. Chairs Dr Eva Polverino Eva is Head of the Research Unit in Respiratory Infections, Department of Respiratory Diseases, Hospital Vall d'Hebron, Barcelona.She is a specialist in respiratory diseases since 2003 and currently Head of the Research Unit in Respiratory Infections of the Department of Respiratory Diseases at Hospital Vall d'Hebron in Barcelona (VHIR, Spain).Eva is currently Director of ERS relationships with the EU and is an ERS representative for different European Projects focused on the fight against antimicrobial resistance.She is author of the European Guidelines on Adult Bronchiectasis and co-chair of EMBARC (European Registry of Bronchiectasis). Prof. Nicolas Roche Nicolas is Professor of Respiratory Medicine at Paris Cité University, and Head of the Department of Respiratory Medicine, Cochin Hospital, Assistance Publique Hôpitaux de Paris - Centre, Paris, France, and a researcher at Paris Cité University.His major areas of interest are chronic obstructive pulmonary disease (COPD), asthma, inhaled therapy and real-life research especially focusing on comparative effectiveness studies.Nicolas is a member of the GOLD scientific Committee and an executive committee member of the Respiratory Effectiveness Group.He is currently serving a three-year-long mandate as ERS Science Council Chair since September 2022. Prof. Michal Shteinberg Michal is a Clinical Associate Professor and a specialist in internal medicine and pulmonology.She is Director of the Bronchiectasis and Adult Cystic Fibrosis Unit at the Carmel Medical Center and the Haifa and Western Galilee District, Clalit Health Services.She is a member of the management board for EMBARC and also sits on the management board for the Israeli Society of Tuberculosis and Mycobacterial diseases. Dr Letizia Traversi Letizia is a pneumologist and clinical researcher, currently enrolled in a Ph.D programme in the Pneumology Department of the Hospital Vall d'Hebron Institut de Recerca, Barcelona. She is also a junior collaborator of EMBARC.Letizia's work focuses on bronchiectasis and its relation to other airway diseases. Additionally, her field of interest includes other aspects of bronchiectasis, such as chronic infection, the transition from pediatric age, and immunodeficiencies. Prof. Dr Felix Ringshausen Professor of Respiratory Medicine and a board-certified Infectious Diseases expert at Hannover Medical School, Germany, where he heads clinics for adults with bronchiectasis, PCD, CF and NTM pulmonary disease.His clinical research interests include clinical trials and complex infections as well as translational and epidemiological aspects of the aforementioned disease areas. Amongst others, he is Principal Investigator of the German Center for Lung Research, Chair of the German Bronchiectasis Registry PROGNOSIS and member of the steering committee of the European Bronchiectasis Registry EMBARC.

  20 November, 2023 | Online18:00-19:00 CETChairs: Dr. Carolina Arez Constant (Lisboa, Portugal), Dr. Ahmad Kantar (Bergamo, Italy)Speakers: Ms. Zena Powell (Aylesbury, United Kingdom), Prof. Andrew Bush (London, United Kingdom), Prof. James D. Chalmers (Dundee, United Kingdom)   Fees: Free for ERS members / €10 for non-membersFind out more about becoming a member   Overview   Non-CF Bronchiectasis is a clinical syndrome of recurrent or persistent wet/productive cough, lower airway infection and/or inflammation, and abnormal bronchial dilatation on chest computed tomography scans. It is a heterogenous chronic pulmonary disorder with many risk factors and aetiologies.   Previously considered irreversible, current data shows that paediatric non-CF bronchiectasis might be reversible over time. Achieving this goal requires early disease recognition leading to appropriate investigations to both diagnose and manage bronchiectasis. Evaluation for treatable underlying causes and effective management are therefore important.   Children/adolescents also require developmentally appropriate care, support and supervision from their parents. Those with untreated non-CF bronchiectasis symptoms from childhood have worse disease and a poorer prognosis. Non-CF Bronchiectasis is still one of the most neglected lung disorders, with high individual disease burden, economic cost and poor quality of life for children/adolescents and their parents. Also, there are large disparities in the standards of care and outcomes between bronchiectasis and other chronic lung diseases.   This webinar will provide an update on current literature on non-CF bronchiectasis and the needs for early disease recognition, prevention and transition from paediatric to adult care.   Moreover, the webinar will offer an opportunity to examine patients experiences, attitudes, preferences, needs, and expectations in patients non-CF bronchiectasis. Patients' perspectives and health goals are at the heart of the care process.   These arguments are among the objectives of the ERS-CRC - Child-BEAR-net (Children's Bronchiectasis Education Advocacy and Research Network). Educational aims To analysis patient experiences, needs and perspectives and the method of patient involvement at different phases of disease managementTo highlight the risks of delayed diagnosis of the underlying causes of non-CF bronchiectasisTo give indications how to improve care for children with non-CF bronchiectasisTo discuss the transition from paediatric to adult care Topics Living with bronchiectasis: a patient perspective - Zena PowellUndiagnosed bronchiectasis in children - Andrew BushOutgrowing pediatric care in bronchiectasis - Stefano Aliberti Target audience: Paediatric pulmonologistsAdult pulmonologistsPaediatriciansInfectious disease specialists Format The webinar will include a patient testimonial, lectures, interactive discussions with participants and two case presentations. Learning outcomes After following this webinar, participants should be able to: Appreciate patients experiences, needs and expectationsRecognise diagnostic errors and delay in diagnosisApprehend how to care for children with non-CF bronchiectasisLaunch developmentally appropriate care and transition from paediatric to adult care CME credit An application for accreditation of this webinar has been made to the European Board for Accreditation in Pneumology (EBAP) for 1 CME credit per 1-hour attendance. If accredited, the CME credit will be granted upon attendance of at least 60 minutes during the live webinar only. What is a webinar? A webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting. During the webinar, you will be asked to share your opinion on issues related to the topic using interactive polls. All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone. Login guidelines More information will be communicated in due course. Please log in to the webinar 20 minutes before it is scheduled to commence. If you have any technical difficulties whilst trying to log in or during the session please contact e-learning@ersnet.org.Check Central European Time.To achieve the best quality, we recommend to avoid downloading anything from the internet during your connection to the lecture and stopping all other programmes.Please also ensure that your audio settings are not set to mute and adjust the volume to a comfortable level.

To take part in this event, you must register in advance. REGISTER NOW   23 March, 2024 10:00-16:00 CET | Online   Overview The European Lung Foundation (ELF) will host its annual Bronchiectasis Patient Conference on 23 March, 2024.   The event will be beneficial for professionals to attend and is open to anyone interested in learning more about bronchiectasis. It will provide insight into the latest clinical findings, treatment and research, alongside real-life patient stories, plus resources and information to help patients live their life well. The conference has been developed with and supported by EMBARC, a pan-European network, and the ELF Bronchiectasis Patient Advisory Group. A live transcription service will allow participants to generate captions in more than 50 languages. This event is free to attend, but registration is required.   Target audience: Respiratory professionals specialising in airway diseases, particularly bronchiectasis Clinicians Early career researchers Patients   Format There will be a mix of live talks and videos from both bronchiectasis patients and medical experts on:   Basic overview for those recently diagnosed or those who need more general information Resources and information to help patients live their life well Bronchiectasis and the future - exciting updates on treatment, research and what lies ahead How to live with bronchiectasis and another airway disease like asthma or COPD Living with the additional challenges of bronchiectasis (sinus, gut, wellbeing etc) Airway clearance - making decisions about the devices and methods available Inspiring stories of what has helped people with bronchiectasis   For full details including an event agenda, please visit the ELF website.   There will be lots of opportunities to ask questions to the speakers.

In the latest episode of Coffee Talk, Prof. Stuart Elborn interviews Prof. Stefano Aliberti and Dr Eva Polverino about the largest ever prospective study of adults with bronchiectasis from 28 countries - the EMBARC study. EMBARC is a European Respiratory Society (ERS) Clinical Research Collaboration. Funded by ERS and the European Union Innovative Medicines Initiative, EMBARC enrolled 16,963 patients across Europe to study the causes, microbiology, severity and outcomes of bronchiectasis across Europe. Bronchiectasis is a growing clinical problem and this new data helps us to understand the best way to investigate and manage bronchiectasis, as well as stimulating new research questions and initiatives to improve quality of care around Europe. Access the article: Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)

European Respiratory Journal 2022 60: 2200300; DOI: 10.1183/13993003.00300-2022 Abstract Bronchiectasis is being diagnosed increasingly in children and adolescents. Recurrent respiratory exacerbations are common in children and adolescents with this chronic pulmonary disorder. Respiratory exacerbations are associated with an impaired quality of life, poorer long-term clinical outcomes, and substantial costs to the family and health systems. The 2021 European Respiratory Society (ERS) clinical practice guideline for the management of children and adolescents with bronchiectasis provided a definition of acute respiratory exacerbations for clinical use but to date there is no comparable universal definition for clinical research. Given the importance of exacerbations in the field, this ERS Task Force sought to obtain robust definitions of respiratory exacerbations for clinical research. The panel was a multidisciplinary team of specialists in paediatric and adult respiratory medicine, infectious disease, physiotherapy, primary care, nursing, radiology, methodology, patient advocacy, and parents of children and adolescents with bronchiectasis. We used a standardised process that included a systematic literature review, parent survey, and a Delphi approach involving 299 physicians (54 countries) caring for children and adolescents with bronchiectasis. Consensus was obtained for all four statements drafted by the panel as the disagreement rate was very low (range 3.6-7.2%). The panel unanimously endorsed the four consensus definitions for 1a) non-severe exacerbation and 1b) severe exacerbation as an outcome measure, 2) non-severe exacerbation for studies initiating treatment, and 3) resolution of a non-severe exacerbation for clinical trials involving children and adolescents with bronchiectasis. This ERS Task Force proposes using these internationally derived, consensus-based definitions of respiratory exacerbations for future clinical paediatric bronchiectasis research.

  ERS and ESPR Joint Webinar16 October, 2023 | Online18:00-19:00 CEST   Paediatric bronchiectasis is a hot topic due to increasing awareness in children and adolescents. It is a chronic pulmonary disorder associated with poor quality of life for the patients and their parents, recurrent exacerbations, and costs to the family and health systems. Educational aims During this session the definition, pathogenesis and underlying causes, radiological findings and treatment of paediatric bronchiectasis will be covered. Cases with paediatric bronchiectasis will be demonstrated with MCQs. Participants will have the opportunity to enrich their knowledge in this entity. Learning objectives: To understand causes and pathogenesis of paediatric bronchiectasisTo familiarise with clinical presentation of pediatric bronchiectasisTo recognise the radiological aspects of this entity

European Lung Foundation (ELF) webinar   This ELF webinar was held to raise awareness about bronchiectasis around the world in the run up to World Bronchiectasis Day (1 July). The webinar is primarily for people with bronchiectasis and their family members or caregivers, but it may also be of interest to professionals in the field of bronchiectasis who would like to understand more about the condition. Professionals could also recommend this recording to their patients.  

  4 July, 2023 | Online18:00-19:00 CEST Educational aims Understand the assessment, management and prevention of exacerbations of bronchiectasis in both non-CF and CF bronchiectasis. Topics Exacerbations bronchiectasis: assessment, management and preventionExacerbations of CF in the modulator era: assessment, management and prevention

European Respiratory Journal 2023 62: 2202053; DOI: 10.1183/13993003.02053-2022AbstractAirway clearance techniques (ACTs) are part of the main management strategy for patients with bronchiectasis. Despite being a priority for patients, accessibility, implementation and reporting of ACTs are variable in clinical settings and research studies. This European Respiratory Society statement summarises current knowledge about ACTs in adults with bronchiectasis and makes recommendations to improve the future evidence base. A task force of 14 experts and two patient representatives (10 countries) determined the scope of this statement through consensus and defined six questions. The questions were answered based on systematic searches of the literature. The statement provides a comprehensive review of the physiological rationale for ACTs in adults with bronchiectasis, and the mechanisms of action along with the advantages and disadvantages of each ACT. Evidence on ACTs in clinical practice indicates that the most frequently used techniques are active cycle of breathing techniques, positive expiratory pressure devices and gravity-assisted drainage, although there is limited evidence on the type of ACTs used in specific countries. A review of 30 randomised trials for the effectiveness of ACTs shows that these interventions increase sputum clearance during or after treatment, reduce the impact of cough and the risk of exacerbations, and improve health-related quality of life. Furthermore, strategies for reducing the risk of bias in future studies are proposed. Finally, an exploration of patients' perceptions, barriers and enablers related to this treatment is also included to facilitate implementation and adherence to ACTs.

The latest episode of Curbside Consult focuses on investigation and management of bronchiectasis. Co-hosts Dr Hitasha Rupani (ERS Learning Resources Director and Chest Physician at the University Hospital Southampton NHS Foundation Trust, UK) and Prof. Dominick Shaw (Professor of Respiratory Medicine at the University of Leicester, UK) are joined by Prof. Stefano Aliberti, Professor of Respiratory Medicine at Humanitas University, Milan, Italy. Hitasha, Dominick and Stefano discuss the case of a 38-year-old female smoker with asthma who was diagnosed with bronchiectasis five years ago. She has a worsening cough and feels unwell. Pseudomonas has been isolated from her sputum.

The latest episode of My Career Path features international experts in the field of bronchiectasis. Host Dr Augusta Beech, Early Career Representative of ERS Assembly 5, is joined by two international experts: Amelia Shoemark, Professor at the University of Dundee where she pioneers research programmes in bronchiectasis and primary ciliary dyskinesia; and Sanjay Chotirmall, Vice Dean and Associate Professor of Molecular Medicine at the Lee Kong Chian School of Medicine, Singapore. The panel share insight into their careers so far to help inform their peers about the experiences, successes and challenges they have faced.

Taking place on 1 June, 2023, this ERS Vision Live panel discussion focused on the current situation and therapeutic perspectives in cystic fibrosis.   The expert panellists discussed these key topics: New therapies - CFTR modulators and gene therapyStrategy for Infection Management New approaches to adult cystic fibrosis patient management   Chairs: - Dr Eva Polverino  Eva Polverino is a specialist in respiratory diseases since 2003 and currently Head of the Research Unit in Respiratory Infections of the Department of Respiratory Diseases at Hospital Vall d'Hebron in Barcelona (VHIR, Spain).She is the current ERS Head of Assembly 10: respiratory infections and is an ERS representative for different European Projects focused on the fight against antimicrobial resistance.Eva's main lines of investigation are non-cystic fibrosis bronchiectasis (NCFBE), cystic fibrosis (CF) and antimicrobial resistance.She is author of the European Guidelines on Adult Bronchiectasis and co-chair of EMBARC (European Registry of Bronchiectasis).   - Mr Dimitris Kontopidis Cystic fibrosis patient and advocate as well as Vice President of the Greek Patient Association, and founder of Patients Hub.He won the European Lung Foundation (ELF) Award in 2021 for his efforts to ensure equal access to innovative treatments and health services for all.   Speakers: - Prof. Stuart Elborn Stuart Elborn is Professor of Medicine and Provost and Deputy Vice-Chancellor (Interim) at Queen's University Belfast. He is also a Visiting Professor at Imperial College London.   Stuart's research interests are in cystic fibrosis and bronchiectasis, focused on identifying new targets and diagnostics for infection and inflammation in lung disease, developing better therapies and the use of digital platforms and artificial intelligence in healthcare delivery.   - Prof. Francesco Blasi, MD, PhD, FERS Francesco Blasi, MD, PhD, FERS is Professor of Respiratory Medicine Department of Pathophysiology and Transplantation at the University of Milan, Italy, as well as Head of Internal Medicine Department and Respiratory Unit of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.   He was formerly President of the European Respiratory Society, President of the Italian Respiratory Society as well as the current President of the Italian Society of Cystic Fibrosis.   - Dr Susan Madge Susan Madge is the Director of the Adult Cystic Fibrosis Centre, Royal Brompton Hospital, London.   Susan has worked with both children and adults with cystic fibrosis (CF) for nearly 40 years. Her particular areas of interest are standards of care, adolescence and end of life.   Susan has been involved with teaching around the world and runs a multi-disciplinary course on CF through the life span in London, which is also available online.

In the latest episode, European Lung Foundation parent-patient representative, Zena Powell, hosts a discussion on childhood bronchiectasis with Prof. Anne Chang, Co-Chair of the ERS Clinical Research Collaboration (CRC) Child-BEAR net Steering Committee and Prof. Andy Bush, Child-BEAR net Steering Committee Member. The Children's Bronchiectasis Education Advocacy and Research Network (Child BEAR net) CRC was launched by ERS in 2021. Find out more about Child BEAR net.

Taking place on 25 April, this ERS Vision Live episode focused on Patient empowerment: literacy and digital opportunities. The expert panellists discussed key areas, including: Remote care: barriers and solutions to sharing health information in a digital worldEngaging patients - new approaches to healthcare professional/patient interactionsData shadow of patients - how to talk to patients about how their health data will be used Chairs: Mr Kjeld Hansen Kjeld Hansen is the Chair of the European Lung Foundation (ELF) and has been associated with ELF since 2012. In his professional capacity, Kjeld is working with digitalisation and is employed by the academic institution Kristiania in Oslo, Norway. In his patient advocacy work, Kjeld is inspired by digitalisation as an enabler for new approaches and organisational forms that put people with respiratory conditions at the centre of the initiative. Dr Tiago Alfaro Tiago is a Pulmonologist in Coimbra, Portugal where he specialises in interstitial lung disease and interventional pulmonology. His involvement in ERS includes being the former Early Career Representative of ERS Assembly 12 - interstitial lung diseases. He has a strong dedication to improving medical research and postgraduate education, focusing on digital opportunities in his native Portugal. Speakers: Dr Vitalii Poberezhets Vitalii is a Ukranian pulmonologist working in the Department of Propaedeutics of Internal Medicine, National Pirogov Memorial Medical University. His clinical interests are mainly in the field of pulmonary medicine involve treatment, management and rehabilitation of patients with COPD and asthma. Within the ERS, he is the Chair of Assembly Group 01.04 - m-Health/e-health and member of Long Range Planning Committee of Assembly 1. Dr Georgia Hardavella MD, MSc, PhD Dr Georgia Hardavella (MD, MSc, PhD) is a Consultant Respiratory Physician at 'Sotiria' Athens' Chest Diseases Hospital in Greece. Her special interests include lung cancer, interventional bronchoscopies and pulmonary nodules. 'Sotiria' is the National Tertiary Referral Centre for Respiratory Diseases in Greece with more than 300 dedicated respiratory beds.She has served as the Chair of the Professional Advisory Committee in the European Lung Foundation (ELF) and she has been involved in numerous ELF projects promoting patient and public involvement in research and clinical services. Ms Barbara Crossley Barbara Crossley has been a member of the ELF Bronchiectasis Patient Advisory Group since 2017.She has helped organise three Bronchiectasis Patient Conferences, collaborated with EMBARC researchers on ongoing projects, helped formulate patient surveys and patient-friendly information for the European Lung Foundation website, and is currently helping develop a patient self-care guide.She has lifelong bronchiectasis and is a writer who lives in the Peak District in Derbyshire, UK.